Study from Imperial College Health Partners Demonstrates Substantial
Economic and Quality of Life Benefits of UroLift System Over
Transurethral Resection of the Prostate
WAYNE, Pa.--(BUSINESS WIRE)--Jun. 8, 2018--
NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX)
focused on addressing unmet needs in the field of urology, today
announced the results of an independent analysis measuring costs and
patient outcomes of the UroLift System compared to transurethral
resection of the prostate (TURP). The study demonstrated that replacing
the current standard of care for men suffering symptoms of benign
prostatic hyperplasia (BPH) with the UroLift® System could
save the National Health System (NHS) approximately £27 million in costs
associated with post-surgical complications.
The study,
conducted by Imperial College Health Partners, also showed significant
quality of life benefits for men treated with the UroLift System when
compared to those treated with TURP. Unlike TURP, the UroLift System
does not involve any cutting or removal of tissue and typically does not
require general anesthesia, post-operative catheterization, or overnight
hospitalization. On average, the hospitalization for men undergoing TURP
is 2.7 days1. The UroLift System is the only minimally
invasive treatment option for BPH that has been shown to provide rapid
and durable symptomatic and urinary flow rate improvement without
inducing sustained sexual dysfunction.2
More than two million men have been diagnosed with BPH in the United
Kingdom3, yet fewer than two percent elect to have surgery.4
Approximately 15,000 TURP procedures are performed across England and
Wales each year for the treatment of BPH.5
“The data analysis from this study sheds new light on the potential cost
savings and improved patient outcomes associated with the prostatic
urethral lift treatment,” said co-author Mr. Oliver Kayes of Leeds
Teaching Hospitals NHS Trust. “Post surgery complications including
urinary tract infections and blood transfusions are expensive
complications of TURP and burdensome to men. The UroLift System offers
men a new minimally invasive option that reduces the occurrence of these
unpleasant side effects.”
“The UroLift System has a demonstrated record of success among patients,
their physicians, and payers in the United States as demonstrated by the
recent addition of the prostatic urethral lift treatment into the
American Urological Association’s new
guidelines on the effective management of BPH,” said Dave Amerson,
president of the Teleflex Interventional Urology business unit. “We are
pleased to see this independent analysis highlighting the economic
benefits to the NHS and improved quality of life British men may
experience with the UroLift System treatment.”
The analysis was recognized as the Best General Poster Research
Presentation at the 2018 International Society For Pharmacoeconomics and
Outcomes Research annual meeting.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive
technology for treating lower urinary tract symptoms due to benign
prostatic hyperplasia (BPH). The UroLift permanent implants, delivered
during a minimally invasive transurethral outpatient procedure, relieve
prostate obstruction and open the urethra directly without cutting,
heating, or removing prostate tissue. Clinical data from a pivotal
206-patient randomized controlled study showed that patients with
enlarged prostate receiving UroLift implants reported rapid and durable
symptomatic and urinary flow rate improvement without compromising
sexual function. Patients also experienced a significant improvement in
quality of life. Nearly 60,000 men have been treated with the UroLift
System in the U.S. Most common adverse events reported include
hematuria, dysuria, micturition urgency, pelvic pain, and urge
incontinence. Most symptoms were mild to moderate in severity and
resolved within two to four weeks after the procedure. The UroLift
System is available in the U.S., Europe, Australia, Canada, Mexico and
South Korea. Learn more at www.UroLift.com.
About Teleflex Interventional Urology
Neotract is now the Teleflex Interventional Urology business unit,
dedicated to developing innovative, minimally invasive and
clinically effective devices that address unmet needs in the field of
urology. Our initial focus is on improving the standard of care for
patients with BPH using the UroLift System, a minimally
invasive permanent implant system that treats symptoms while preserving
normal sexual function. Learn more at www.UroLift.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to
improve the health and quality of people’s lives. We apply purpose
driven innovation – a relentless pursuit of identifying unmet clinical
needs – to benefit patients and healthcare providers. Our portfolio is
diverse, with solutions in the fields of vascular and interventional
access, surgical, anesthesia, cardiac care, urology, emergency medicine
and respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For more
information, please visit www.teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®,
Rusch®, UroLift® and Weck® – trusted brands united by a common sense of
purpose.
1https://imperialcollegehealthpartners.com/wp-content/uploads/2018/05/Neotract_ISPOR_v7-2.pdf
2
No instances of new, sustained erectile or ejaculatory dysfunction
McVary; Roehrborn, J Urology 2013 LIFT Study.
3 Trueman,
BJU Intl 1999; 83: 410-415
4van Exel, NJA et al., Eur
Urol 2006; 49: 92-102
5https://www.nice.org.uk/guidance/mtg23/documents/the-turis-system-for-transurethral-resection-of-the-prostate-final-scope2
View source version on businesswire.com: https://www.businesswire.com/news/home/20180608005140/en/
Source: Teleflex Incorporated
For Teleflex Incorporated:
Jake Elguicze, 610-948-2836
Treasurer
and Vice President, Investor Relations
or
Media:
Nicole
Osmer, 650-454-0505
nicole@healthandcommerce.com